in vivo applications of next-generation DDS carrier for achieving less-invasive radiation therapy

2016 Fiscal Year Final Research Report

• Project/Area Number: 15K21156
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Tumor therapeutics; Biomedical engineering/Biomaterial science and engineering
• Research Institution: Kobe University
• Principal Investigator: Nishimura Yuya 神戸大学, 科学技術イノベーション研究科, 特命助教 (40728218)
• Project Period (FY): 2015-04-01 – 2017-03-31
• Keywords: ドラッグデリバリーシステム / バイオナノカプセル / 抗癌剤ドキソルビシン / 放射線増感剤 / ナノ粒子 / 放射線治療 / Affibody / in vivo

Outline of Final Research Achievements

We have developed bio-nanocapsule derived from hepatitis B virus as a carrier for drug delivery system and achieved some progress in vitro. Therefore, to apply this carrier in a clinical application, we demonstrated availability in vivo. As the result, delivery of anticancer drug (doxorubicin) showed antitumor effect in mouse xenograft models. Next, we measured time course of biodistribution of PAATiOx with radiosensitization efficacy and showed accumulation within the tumor. Then, in combination with X-irradiation, antitumor effect was observed. Therefore, we indicated that this carrier is available in vivo.

Free Research Field

バイオプロダクション